| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Zhang,Nian-Yuan | Chairman | 0.42% | |
| Zheng,Jia-Jing | Director | 14.62% | NATIONAL DEVELOPMENT FUND MANAGEMENT COMMITTEE, EXECUTIVE YUAN |
| Lin,Shi-Jia | Director | 14.62% | NATIONAL DEVELOPMENT FUND MANAGEMENT COMMITTEE, EXECUTIVE YUAN |
| Chen,Zhi-Quan | Director | 0.24% | ZHANG CHUN INVESTMENT CO., LTD. |
| Li,Tian-Jie | Director | 6.63% | HUI HONG INVESTMENT CO., LTD. |
| Ceng,Da-Meng | Director | 1.05% | YI TAI INVESTMENT CO., LTD. |
| Qiu,Qin-Ting | Independent Director | 0.00% | |
| Lin,Guo-Feng | Independent Director | 0.00% | |
| Li,Shi-Ren | Independent Director | 0.00% |
Change Capital to 4,000,000,000
2024/07/03
Change Company Name to Taimed Biologics Inc.
2023/11/30
Change Company Name to Taimed Biologics Inc.
2023/09/01
Change Company Name to ZHONGYU NEW DRUG CO., LTD. (FORMER NAME: YUCHANG BIOTECHNOLOGY CO., LTD.)
2023/09/01
Change Company Name to Taimed Biologics Inc.
2023/06/01
Change Company Name to ZHONGYU NEW DRUG CO., LTD. (FORMER NAME: YUCHANG BIOTECHNOLOGY CO., LTD.)
2023/06/01
Change Company Name to Taimed Biologics Inc.
2023/03/07
Change Company Name to ZHONGYU NEW DRUG CO., LTD. (FORMER NAME: YUCHANG BIOTECHNOLOGY CO., LTD.)
2023/03/07
Change Company Name to ZHONGYU NEW DRUG CO., LTD. (FORMER NAME: YUCHANG BIOTECHNOLOGY CO., LTD.)
2022/12/05
Change Company Name to ZHONGYU NEW DRUG CO., LTD. (FORMER NAME: YUCHANG BIOTECHNOLOGY CO., LTD.)
2022/09/06
Change Company Name to Taimed Biologics Inc.
2022/09/06
Change Capital to 3,000,000,000
2019/05/14
Change Person in Charge to Zhang,Nian-Yuan
2018/05/09
Change Capital to 2,600,000,000
2015/12/17
Change Person in Charge to Chen,Zhi-Quan
2013/06/21
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 610,162 | 491,777 | 563,008 |
| Operating cost | 398,937 | 266,544 | 347,297 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 211,225 | 225,233 | 215,711 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 211,225 | 225,233 | 215,711 |
| Operating expenses | 463,493 | 391,464 | 407,567 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -252,268 | -166,231 | -191,856 |
| Non-operating income and expenses | 50,436 | -28,579 | -77,433 |
| Net profit (loss) before tax | -201,832 | -194,810 | -269,289 |
| Income tax expense (benefits) | 0 | 0 | 0 |
| Net profit (loss) of ongoing business for the current period | -201,832 | -194,810 | -269,289 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -201,832 | -194,810 | -269,289 |
| Other comprehensive profit (loss), net | -7,763 | 183 | 20,136 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -209,595 | -194,627 | -249,153 |
| Net profit (loss) attributable to owners of parent company | -201,832 | -194,810 | -269,289 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | -209,595 | -194,627 | -249,153 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 0 | 0 | -1 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | -379,552 | -25,601 | -605,210 |
| Net cash inflows (outflows) from investing activities | -714,842 | -16,455 | 106,115 |
| Net cash inflow (outflow) from financing activities | 1,412,079 | 19,232 | 208,382 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 11,538 | -279 | 13,205 |
| Increase (decrease) in cash and cash equivalents in the current period | 329,223 | -23,103 | -277,508 |
| Beginning balance of cash and cash equivalents | 251,007 | 274,110 | 551,618 |
| Ending balance of cash and cash equivalents | 580,230 | 251,007 | 274,110 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 3,393,658 | 2,151,398 | 2,164,993 |
| Non-current asset | 1,605,589 | 1,742,524 | 1,936,119 |
| Total asset | 4,999,247 | 3,893,922 | 4,101,112 |
| Current liability | 134,765 | 361,172 | 329,863 |
| Non-current liability | 841,573 | 966,664 | 1,056,325 |
| Total liability | 976,338 | 1,327,836 | 1,386,188 |
| share capital | 2,730,815 | 2,530,097 | 2,525,530 |
| Equity - secruity token | - | - | - |
| capital reserve | 2,452,372 | 986,672 | 945,450 |
| retained earning | -1,136,387 | -934,555 | -740,222 |
| Other equity | -23,891 | -16,128 | -15,834 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 4,022,909 | 2,566,086 | 2,714,924 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 4,022,909 | 2,566,086 | 2,714,924 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 14 | 10 | 10 |
